AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01436240 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire administration followed by cognitive interviews
Description: Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
Study NCT01037686 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Injection of 15mCi of Tc-ECD and scanning by SPECT camera
Description: All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
Study NCT01037686 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Semantic verbal fluency task performance
Description: All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
Study NCT01037686 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Turning off the stimulator
Description: For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
Study NCT04628312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static footprint
Description: The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
Study NCT01732770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection once every 6 months.
Study NCT01732770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg administered by intravenous infusion once a year
Study NCT01732770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 6 months
Study NCT01732770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Zoledronic Acid
Description: Administered by intravenous infusion once a year
Study NCT04327024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol.
Study NCT04327024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
Study NCT04327024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for verinurad
Description: Matching Capsule
Study NCT04327024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for allopurinol
Description: Matching tablet
Study NCT00791089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOVAZA Omega 3-acid ethyl esters
Description: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
Study NCT00791089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOVAZA
Description: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
Study NCT00791089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group will receive placebo before \& after ablation.
Study NCT04406025 — intervention group
Intervention type: PROCEDURE
Intervention: participation in Regional Anesthesia Seminar
Description: this group of anesthesiologists attended the Regional Anesthesia Seminar
Study NCT04406025 — intervention group
Intervention type: PROCEDURE
Intervention: no participation in Regional Anesthesia Seminar
Description: this group of anesthesiologists did not attend the Regional Anesthesia Seminar
Study NCT03986528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection+Chemotherapy
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
Study NCT03986528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
Study NCT00321464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
Study NCT00321464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Study NCT01318837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study NCT00610311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Study NCT00610311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
Study NCT01581463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine, Sodium
Description: Single 100-microgram (2 X 50 microgram) dose.
Study NCT02166190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation using EndoHPB Probe
Description: Radiofrequency Ablation using EndoHPB Probe
Study NCT02166190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting only
Description: Stenting only
Study NCT01457599 — intervention group
Intervention type: PROCEDURE
Intervention: Computertomography-guided marking of colorectal liver metastases
Description: Computertomography-guided marking of colorectal liver metastases
Study NCT03033017 — intervention group
Intervention type: OTHER
Intervention: Blood Testing
Study NCT02859649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological test
Description: neuropsychological test
Study NCT01321788 — intervention group
Intervention type: DRUG
Intervention: TINZAPARIN
Description: Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Study NCT01321788 — intervention group
Intervention type: DRUG
Intervention: PLACEBO
Description: Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
Study NCT01102413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer
Description: Infusion or injections
Study NCT01102413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulphate
Description: Oral intake
Study NCT03219697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting education program
Description: 8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
Study NCT00816699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: preprint preoperative anesthetic risk information
Description: preprint preoperative anesthetic risk information
Study NCT00816699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preprint preoperative anesthetic risk information
Description: preprint preoperative anesthetic risk information
Study NCT01290848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take TIME Health Campaign
Description: 1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children.
Study NCT00610311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
Study NCT00610311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC gp100 Vaccine
Description: 0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)
Study NCT00610311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
Description: 3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.
Study NCT03590353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Chamber Pacemaker
Description: 1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
Study NCT03590353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His Bundle Pacemaker
Description: 1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
Study NCT01206582 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hemin
Description: 10 iv infusions for 8 weeks
Study NCT01308190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (Xeloda)
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Study NCT01308190 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50.4 Gy
Description: Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
Study NCT01308190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal Endoscopic Microsurgery
Description: 6-8 weeks after Chemoradiotherapy
Study NCT01308190 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Mesorectal Excision
Description: Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
Study NCT01381861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
Study NCT03155009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600 mg orally BID with food
Study NCT00554671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm driven medication titration
Description: Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
Study NCT00554671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
Study NCT00554671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group support
Description: Peer support are provided in the group setting
Study NCT01206582 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: 10 iv infusions for 8 weeks
Study NCT01363661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coruno
Description: Molsidomine 16 mg tablet, per os, once a day
Study NCT01363661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (16 mg tablet, per os; once-daily)
Study NCT03688074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT03688074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel capsules (600 mg) at end of PCI
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel capsules (600 mg) at end of PCI
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bolus & placebo infusion
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules - end of PCI
Description: Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
Study NCT00385138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules - end of infusion
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Study NCT02629822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/lamivudine/tenofovir disoproxil fumarate
Description: FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
Study NCT03679624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib, 420mg orally, once daily
Study NCT04533204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mnemonic strategy training
Description: training using mnemonic strategies
Study NCT04533204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: spaced retrieval training
Description: training using spaced retrieval
Study NCT00005803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous transplantation
Study NCT00005803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Description: Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03679624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
Study NCT00741013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill and placebo IV
Description: Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00005803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00005803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00005803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic transplantation
Study NCT00005803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic transplantation
Study NCT00005803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Lymphocytes
Description: IV donor lymphocyte infusion
Study NCT00005803 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo radiotherapy
Study NCT02301468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
Study NCT02301468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Compression
Description: (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.